Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica

Multiple Sclerosis and Related Disorders

Volumn 3, Issue 2, 2014, Pages 244-252

  Graves, Jennifer ^a   Vinayagasundaram, Uma ^a   Mowry, Ellen M ^a   Matthews, Ian R ^a   Marino, Julia A ^a   Cheng, Jing ^a   Waubant, Emmanuelle ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Demyelinating diseases; Immunology; Monoclonal antibodies; Multiple sclerosis; Neuromyelitis optica; Rituximab

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MITOXANTRONE; RITUXIMAB; STEROID;

ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; DEATH; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG SAFETY; FEMALE; FOLLOW UP; HERPES VIRUS INFECTION; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NATURAL KILLER CELL; RECURRENT DISEASE; SINUSITIS; T LYMPHOCYTE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84892785246     PISSN: 22110348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.msard.2013.10.003     Document Type: Article

References (28)

1. DR Anderson, A Grillo-Lopez, C Varns, KS Chambers, and N. Hanna Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma Biochem Soc Trans 25 1997 705 708
2. JJ Archelos, MK Storch, and HP. Hartung The role of B cells and autoantibodies in multiple sclerosis Ann Neurol 47 2000 694 706
3. JR Avasarala, AH Cross, and JL. Trotter Oligoclonal band number as a marker for prognosis in multiple sclerosis Arch Neurol 58 2001 2044 2045
4. A Bar-Or, PA Calabresi, D Arnold, C Markowitz, S Shafer, and LH Kasper et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial Ann Neurol 63 2008 395 400
5. SE Baranzini, MC Jeong, C Butunoi, RS Murray, CC Bernard, and JR. Oksenberg B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions J Immunol 163 1999 5133 5144
6. TA Barr, P Shen, S Brown, V Lampropoulou, T Roch, and S Lawrie et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells J Exp Med 209 2012 1001 1010
7. M Colombo, M Dono, P Gazzola, S Roncella, A Valetto, and N Chiorazzi et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients J Immunol 164 2000 2782 2789
8. SL. Constant B lymphocytes as antigen-presenting cells for CD4+ T cell priming in vivo J Immunol 162 1999 5695 5703
9. MS Cragg, CA Walshe, AO Ivanov, and MJ. Glennie The biology of CD20 and its potential as a target for mAb therapy Curr Dir Autoimmun 8 2005 140 174
10. BA Cree, S Lamb, K Morgan, A Chen, E Waubant, and C. Genain An open label study of the effects of rituximab in neuromyelitis optica Neurology 64 2005 1270 1272
11. AH Cross, RS Klein, and L. Piccio Rituximab combination therapy in relapsing multiple sclerosis Ther Adv Neurol Disord 5 2012 311 319
12. AH Cross, JL Stark, J Lauber, MJ Ramsbottom, and JA. Lyons Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients J Neuroimmunol 180 2006 63 70
13. M Duddy, and A. Bar-Or B-cells in multiple sclerosis Int MS J 13 2006 84 90
14. M Duddy, M Niino, F Adatia, S Hebert, M Freedman, and H Atkins et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis J Immunol 178 2007 6092 6099
15. AJ Fay, EM Mowry, J Strober, and E. Waubant Relapse severity and recovery in early pediatric multiple sclerosis Mult Scler 18 2012 1008 1012
16. CP Genain, B Cannella, SL Hauser, and CS. Raine Identification of autoantibodies associated with myelin damage in multiple sclerosis Nat Med 5 1999 170 175
17. SL Hauser, E Waubant, DL Arnold, T Vollmer, J Antel, and RJ Fox et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis N Engl J Med 358 2008 676 688
18. DK Kitsos, S Tsiodras, E Stamboulis, and KI. Voumvourakis Rituximab and multiple sclerosis Clin Neuropharmacol 35 2012 90 96
19. JF. Kurtzke Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1983 1444 1452
20. K Lehmann-Horn, E Schleich, D Hertzenberg, A Hapfelmeier, T Kumpfel, and N von Bubnoff et al. Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders J Neuroinflamm 8 2011 146
21. E Meinl, M Krumbholz, and R. Hohlfeld B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation Ann Neurol 59 2006 880 892
22. H Morbach, EM Eichhorn, JG Liese, and HJ. Girschick Reference values for B cell subpopulations from infancy to adulthood Clin Exp Immunol 162 2010 271 279
23. RT Naismith, L Piccio, JA Lyons, J Lauber, NT Tutlam, and BJ Parks et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial Neurology 74 2010 1860 1867
24. JE Olsson, and H. Link Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remissions Arch Neurol 28 1973 392 399
25. L Piccio, RT Naismith, K Trinkaus, RS Klein, BJ Parks, and JA Lyons et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis Arch Neurol 67 2010 707 714
26. CH Polman, SC Reingold, G Edan, M Filippi, HP Hartung, and L Kappos et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" Ann Neurol 58 2005 840 846
27. ME Reff, K Carner, KS Chambers, PC Chinn, JE Leonard, and R Raab et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 1994 435 445
28. MS Weber, T Prod'homme, JC Patarroyo, N Molnarfi, T Karnezis, and K Lehmann-Horn et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity Ann Neurol 68 2010 369 383